血浆中的Mir-421作为癌前胃病变和早期胃癌的潜在诊断生物标志物。
Mir-421 in plasma as a potential diagnostic biomarker for precancerous gastric lesions and early gastric cancer.
作者信息
Chen Jianlin, Wu Lihua, Sun Yifan, Yin Qi, Chen Xianhua, Liang Siqun, Meng Qingyan, Long Haihua, Li Fangying, Luo Changjun, Xiao Xiaorong
机构信息
Department of Clinical Laboratory, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Department of Digestive Internal Medicine, Affiliated Liutie Central Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
出版信息
PeerJ. 2019 Jun 17;7:e7002. doi: 10.7717/peerj.7002. eCollection 2019.
OBJECTIVE
MicroRNA (miR)-421 plays a key role in cancer progression. It has been reported that circulating miR-421may be a potential tumor marker for the diagnosis of several cancers. However, the role of miR-421 in plasma as a potential biomarker in the diagnosis of precancerous gastric lesions (Pre) and early-stage gastric cancer (GC) remains poorly understood. In this study, we investigated miR-421 in plasma as a novel potential biomarker for the detection of precancerous gastric lesions and early-stage (GC).
MATERIALS & METHODS: The miRNA content was determined by quantitative real-time polymerase chain reaction (qRT-PCR). MiR-421 content in all subjects was normalized by endogenous miRNA (miR-16). The diagnostic value of miR-421 for Pre and GC was assessed by comparing receiver operating characteristic (ROC) analysis with traditional tumor markers, including CEA, CA125, CA153, CA211 and CA50. The correlation between the expression of miR-421 and the pathological characteristics of Pre and GC was analyzed.
RESULTS
Elevated expression of miR-421 in plasma can robustly distinguish the normal population from Pre and GC cases, especially in the early stages of gastric cancer cases (all < 0.05). The ROC analyses showed that the area under the ROC curve (AUC), sensitivity, accuracy and Youden index of miR-421 were superior to traditional tumor markers (CEA, CA125, CA153, CA211, and CA50) in GC diagnosis, while its specificity was higher than CEA, CA153 and CA50 (all < 0.05). MiR-421 in plasma had higher AUC value than AFP, CA153, CA211 and CA50 in the diagnosis of Pre (all < 0.05), while specificity, accuracy and Youden index of miR-421 was only lower than CA211. The efficiency of miR-421 in the diagnosis of GC was significantly higher than that of CA211 and CA50, and it was significantly higher than CA153, CA211 and CA50 in the diagnosis of Pre (all < 0.05). In addition, up-regulation of miR-421 occurred initially in precancerous gastric lesions as well as in the early stage of GC.
CONCLUSIONS
Overexpression of plasma miR-421 is a novel biomarker for the detection of precancerous lesions and early gastric cancer.
目的
微小RNA（miR）-421在癌症进展中起关键作用。据报道，循环miR-421可能是几种癌症诊断的潜在肿瘤标志物。然而，miR-421在血浆中作为癌前胃病变（Pre）和早期胃癌（GC）诊断的潜在生物标志物的作用仍知之甚少。在本研究中，我们研究了血浆中的miR-421作为检测癌前胃病变和早期（GC）的新型潜在生物标志物。
材料与方法
通过定量实时聚合酶链反应（qRT-PCR）测定miRNA含量。所有受试者的miR-421含量通过内源性miRNA（miR-16）进行标准化。通过将受试者工作特征（ROC）分析与传统肿瘤标志物（包括癌胚抗原、CA125、CA153、CA211和CA50）进行比较，评估miR-421对Pre和GC的诊断价值。分析miR-421表达与Pre和GC病理特征之间的相关性。
结果
血浆中miR-421表达升高可有效区分正常人群与Pre和GC病例，尤其是在早期胃癌病例中（所有P<0.05）。ROC分析显示，miR-421在GC诊断中的ROC曲线下面积（AUC）、敏感性、准确性和尤登指数均优于传统肿瘤标志物（癌胚抗原、CA125、CA153、CA211和CA50），而其特异性高于癌胚抗原、CA153和CA50（所有P<0.05）。血浆中的miR-421在Pre诊断中的AUC值高于甲胎蛋白、CA153、CA211和CA50（所有P<0.05），而miR-421的特异性、准确性和尤登指数仅低于CA211。miR-421在GC诊断中的效率显著高于CA211和CA50，在Pre诊断中显著高于CA153、CA211和CA50（所有P<0.05）。此外，miR-421的上调最初发生在癌前胃病变以及GC的早期阶段。
结论
血浆miR-421的过表达是检测癌前病变和早期胃癌的新型生物标志物。
Zotero 插件